Kenvue Stock News

Kimberly-Clark is readying concessions to address ​EU antitrust concerns about ‌its bid for Tylenol maker Kenvue that could help ​it win approval ​for the $40 billion deal after ⁠a preliminary review, ​people familiar with the matter ​said.

Owning consumer staples stocks is an absolute must in a dividend investing strategy. Most people turn to dividend stocks for two reasons — to generate income or to put the magic of compounding to work using dividend reinvestment to amplify wealth building over time.

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.21 per share on its common stock. The quarterly dividend is payable on October 2, 2026, to shareholders of record as of the close of business on September 21, 2026. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Bu...

Australia's competition regulator on Wednesday approved Kimberly-Clark's proposed $40 billion takeover of Kenvue , ​on condition the company divests Kenvue's Carefree ‌and Stayfree period care brands in the country to address competition concerns.

Kimberly-Clark has asked EU regulators permission ​for its proposed $40 billion takeover ‌of Tylenol maker Kenvue, documents on the EU ​Commission's website showed.

Accomplished legal executive and global litigator brings proven track record of enterprise risk management and strategic leadership to support Kimberly-Clark's next chapter of growth DALLAS, Aug. 13, 2026 /PRNewswire/ -- Kimberly-Clark Corporation (NASDAQ: KMB) today announced the appointment of Suzana Blades as Senior Vice President and General Counsel, effective September 1, 2026. She will re...

Kenvue Inc (NYSE:KVUE) shares fell about 2% on Thursday after the consumer health company reported second quarter results that narrowly missed Wall Street expectations, while margins declined from a year earlier. The company reported adjusted diluted earnings per share of $0.31, compared with the $0.32 consensus estimate.

Kenvue narrowly missed Wall Street estimates for second-quarter results on Thursday as inflation, tariffs ​and currency-related costs squeezed margins.